Prevymis (letermovir) - Merck (MSD)
Strategies for management of human cytomegalovirus (HCMV) reactivation in haematopoietic stem cell transplant recipients (HSCTRs) in the era of letermovir (ESCMID Global 2026) - Feb 4, 2026 - Abstract #O0925; Pres time: Apr 21, 2026; 11:24 AM - 11:36 AM; Location: Hall A2-2; No abstract available 
Clinical • Cytomegalovirus Infection • Transplantation
https://www.escmid.org/congress-events/escmid-global/programme/preliminary-programme/
 
I. Cassaniti; D. Mele; M. Michele; F. Zavaglio; G. Grassia; N. Polverelli; D. Russo; A. Algarotti; T. Lazzarotto; F. Bonifazi; P. Chiusolo; F. Baldanti; D. Lilleri
 
Feb 4, 2026
 
Prev Next